Orthofix International NV (OFIX) : Mitra Capital added new position in Orthofix International NV during the most recent quarter end. The investment management firm now holds 121,022 shares of Orthofix International NV which is valued at $5,268,088 , the company said in a statement filed on Aug 12, 2016 with the SEC.Orthofix International NV makes up approximately 8.26% of Mitra Capital’s portfolio.
Other Hedge Funds, Including , Argentus Capital Management reduced its stake in OFIX by selling 2,681 shares or 22.8% in the most recent quarter. The Hedge Fund company now holds 9,080 shares of OFIX which is valued at $395,252. Orthofix International NV makes up approx 0.17% of Argentus Capital Management’s portfolio.Blackrock Fund Advisors reduced its stake in OFIX by selling 16,108 shares or 3.38% in the most recent quarter. The Hedge Fund company now holds 460,612 shares of OFIX which is valued at $20,050,440.Gamco Investors Et Al reduced its stake in OFIX by selling 2,800 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 96,325 shares of OFIX which is valued at $4,086,107. Orthofix International NV makes up approx 0.03% of Gamco Investors Et Al’s portfolio.
Orthofix International NV opened for trading at $43.2 and hit $44.22 on the upside on Monday, eventually ending the session at $44.13, with a gain of 1.80% or 0.78 points. The heightened volatility saw the trading volume jump to 88,886 shares. Company has a market cap of $800 M.
On the company’s financial health, Orthofix International NV reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 1, 2016. Analyst had a consensus of $0.33. The company had revenue of $104.08 million for the quarter, compared to analysts expectations of $102.40 million. The company’s revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 EPS.
Orthofix International N.V. (Orthofix) is a diversified global medical device company focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians across the world. The company operates in four segments: BioStim Biologics Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim Spinal-Stim and Physio-Stim. Its Biologic solutions products include AlloQuent Structural Allografts Trinity ELITE and Trinity Evolution among others. Its Extremity Fixation solutions include Fixator and Galaxy Fixation System among others. Its Spine Fixation solutions products include NewBridge Laminoplasty Fixation System and PILLAR PL & TL PEEK VBR System among others. It uses independent distributors as well as directly distributes its products in the United States Italy the United Kingdom Germany Switzerland Austria France Brazil Australia and Puerto Rico.